cro.directory
← Home
Sciomics GmbH logo

Sciomics GmbH

Precision Proteomics: high-content antibody microarray protein and PTM profiling

Sciomics provides antibody microarray proteomics, with panels profiling hundreds to over 1,500 proteins and PTMs from minimal sample input. Its services support biomarker discovery, target validation, and patient stratification for pharma and biotech partners. Headquartered in Neckargemünd, Germany.

Phases

Indications / Therapeutic Areas

Services

About this organization

Overview

Sciomics is a contract research and biomarker development company specialising in Precision Proteomics. It supports pharma, biotech, and academic partners with antibody microarray-based protein profiling and post-translational modification (PTM) screening.

Services

  • Study design and planning: alignment of research objectives, biomarker hypotheses, assay selection, and sample strategy.
  • Affinity proteomics profiling: multiplex protein profiling on proprietary antibody microarrays, with optional PTM screening.
  • Data analysis and reporting: statistical and bioinformatic analysis to identify differentially expressed proteins and pathway alterations, delivered as a structured report.
  • Result interpretation: review of results with the client, interpretation of biological relevance, and discussion of next experimental or translational steps.

Platform

The antibody microarray portfolio includes scioCyto, scioCD, scioDiscover, scioPhospho, and scioUbi. Arrays analyse hundreds to more than 1,500 proteins, with optional PTM screening, for cytokine and immune profiling, intracellular signalling, and pathway analysis.

Sample types include plasma, serum, CSF, tissues, cell lysates, supernatants, and organoid systems. The platform is described as delivering reproducible results from minimal sample input.

Applications

  • Preclinical drug studies and dose optimisation
  • Mechanism-of-action analysis
  • Target identification and pathway validation
  • Protein biomarker discovery, verification, and validation
  • Translational biomarker development for clinical research
  • Patient stratification and therapy response prediction
  • Oncology research and tumour microenvironment analysis

Internal pipeline

Alongside its services, Sciomics develops internal multi-protein biomarker programs. Its most advanced program is in acute kidney injury (AKI), described as validated in large patient cohorts.

Locations

  • Headquarters

    Neckargemünd · Germany

Similar profiles by shared services, phases, and indications.

View all alternatives →See similar CROs ranked by shared capabilities

Submit a verified review for this organization.

Markdown mirror: /companies/sciomics.md